e-Therapeutics plc announced consolidated unaudited earnings results for six months ended July 31, 2018. For the period, the company reported operating loss of £2,793,000 compared to £3,707,000 a year ago. Loss before tax was £2,780,000 compared to £3,682,000 a year ago. Loss attributable to equity holders of the Company was £2,177,000 compared to £2,969,000 a year ago. Loss per basic and diluted share was 0.81 pence compared to 1.11 pence a year ago. Net cash used in operating activities was £1,955,000 compared to £1,540,000 a year ago. Acquisition of property, plant and equipment amounted to £5,000 compared to £53,000 a year ago. Acquisition of other intangible assets amounted to £15,000.

Based on the company's current strategy, and assuming no income in the period, it is likely that there will be a further reduction in the operating loss in the second half when compared to the first half. This reduction reflects an ongoing cost reduction plan and anticipated lower spend on the two core drug discovery projects.